Sustained complete molecular remission after imatinib discontinuation in children with chronic myeloid leukemia
Moser O, Krumbholz M, Thiede C, Tauer JT, Janz I, Lauten M, Dilloo D, Metzler M, Suttorp M (2014)
Publication Type: Journal article
Publication year: 2014
Journal
Publisher: Wiley-Blackwell
Book Volume: 61
Pages Range: 2080-2
Journal Issue: 11
DOI: 10.1002/pbc.25090
Abstract
Approximately 40% of adults with chronic myeloid leukemia (CML) in prolonged complete molecular response (CMR) remain in CMR after imatinib discontinuation. Corresponding information in children is lacking. Two children with CML in CMR for 48 and 19 months after imatinib discontinuation showed low-level fluctuating disease at RNA transcript and genomic DNA levels. Both patients were low risk according to adult criteria. Since adults with molecular relapse responded to re-introduction of imatinib, we postulated that treatment discontinuation in low risk children might be justified within clinical trials with close monitoring. This may help to minimize exposure to imatinib and its potential side effects.
Authors with CRIS profile
Manuela Krumbholz
Department of Paediatrics and Adolescent Medicine
Markus Metzler
Professur für Kinder- und Jugendmedizin mit dem Schwerpunkt Pädiatrische Onkologie und Hämatologie
Involved external institutions
Universitätsklinikum Bonn
Germany (DE)
Technische Universität Dresden
Germany (DE)
Universitätsklinikum Schleswig-Holstein (UKSH)
Germany (DE)
Germany (DE)
Technische Universität Dresden
Germany (DE)
Universitätsklinikum Schleswig-Holstein (UKSH)
Germany (DE)
How to cite
APA:
Moser, O., Krumbholz, M., Thiede, C., Tauer, J.T., Janz, I., Lauten, M.,... Suttorp, M. (2014). Sustained complete molecular remission after imatinib discontinuation in children with chronic myeloid leukemia. Pediatric Blood & Cancer, 61(11), 2080-2. https://doi.org/10.1002/pbc.25090
MLA:
Moser, Olga, et al. "Sustained complete molecular remission after imatinib discontinuation in children with chronic myeloid leukemia." Pediatric Blood & Cancer 61.11 (2014): 2080-2.
BibTeX: Download